Treating benign prostate hyperplasia with SARMS

Abstract

This invention provides a method of treating, preventing, suppressing, inhibiting or reducing the incidence of benign prostate hyperplasia in a male subject, by administering to the subject a selective androgen receptor modulator (SARM) and / or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof as described herein. This invention also provides a method of treating a subject suffering from hair loss, comprising the step of administering to the subject a therapeutically effective amount of a 5-α reductase enzyme type 1 and / or type 2 inhibitor, wherein said inhibitor is a selective androgen receptor modulator (SARM) and / or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof as described herein. This invention also provides a method of inhibiting a 5-α reductase type 1 and / or type 2 enzyme, comprising contacting the enzyme with an effective 5-α reductase inhibitory amount of a selective androgen receptor modulator (SARM) and / or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or any combination thereof, as described herein.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This Application claims priority of Provisional Application Ser. No. 60,354,300, filed Feb. 7, 2002 and Provisional Application Ser. No. 60,362,997, filed Mar. 11, 2002, which are hereby incorporated by reference.FIELD OF INVENTION[0002]This invention relates to the prevention and / or treatment of benign prostate hyperplasia (BPH). More particularly, this invention relates to a method of treating, preventing, suppressing, inhibiting, or reducing benign prostate hyperplasia in a male subject suffering from benign prostate hyperplasia, comprising administering to said subject a selective androgen receptor modulator and / or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, or mixtures thereof.BACKGROUND OF THE INVENTION[0003]Benign prostate hyperplasia (BPH) is a nonmalignant enlargement of the prostate gland. BPH is the most common non-malignant proliferative abnormality fo...

AI Technical Summary

Benefits of technology

[0096]In one embodiment, the Compound I-VI prevents recruitment of co-activators or co-regulators of androgen-responsive DNA and prevents growth of AR-dependent cells (such as glandular epithelium in prostate). In one embodiment, the compound is Compound II. In another embodiment, the compound is Compound VI.

[0097]In one embodiment, the Compound I-VI prevents recruiting co-repressors of androgen-responsive DNA and prevents growth of AR-dependent cells (such as glandular epithelium in prostate). In one embodiment, the compound is Compound II. In another embodiment, the compound is Compound VI.

[0098]In one embodiment, the Compound I-VI prevents mitogenic action of Testosterone and DHT by blocking the ability of endogenous ligands to bind the receptor and induces the transcription of other hormones and growth factors which signal in a paracrine fashion to induce proliferation of prostate epithelium. In one embodiment, the compound is Compound II. In another embodiment, the compound is Compound VI.

[0099]In one embodiment, the Compound I-VI prevents mitogenic action of Testosterone and DHT by blocking the ability of endogenous ligands to bind the receptor and induce downstream molecular signaling which induce programmed cell death of glandular epithelium. In one embodiment, the compound is Compound II. In another embodiment, the compound is Compound VI.

[0100]The present invention provides a safe and effective method of treating, preventing, suppressing, inhibiting or reducing the incidence of BPH and is particularly useful in treating male subjects suffering from symptoms and signs of BPH.

Problems solved by technology

This causes patients to experience a frequent urge to urinate because of incomplete emptying of the bladder and a burning sensation or similar discomfort during urination.

The obstruction of urinary flow can also lead to a general lack of control over urination, including difficulty initiating urination when desired, as well as difficulty of urinary retention because bladder outlet obstruction and a uncontrollable urinary continence due to residual urine, a condition known as overflow urinary incontinence.

The first component is due to enlargement of the prostate gland, which may result in compression of the urethra and obstruction to the flow of urine from the bladder.

This action, in turn, induces protein synthesis and abnormal growth of the prostate.

Surgical procedures, while effective in relieving the symptoms of BPH, result in substantial damage being inflicted upon the prostatic urethra.

Laser assisted prostatectomy and heat ablation therapies, while less invasive, also cause substantial damage to the prostatic urethra.

As well, surgical treatment of BPH is estimated to cost over a billion dollars per year, with the expectation that these costs will rise as the aged male population increases.

BPH, if left unabated, can have dire health consequences.

BPH can lead to acute urinary retention (complete inability to urinate), serious life threatening urinary tract infections and urosepsis and permanent bladder and kidney damage.

Images